Start practicing

Pharmacology · single question

Humira (adalimumab) mechanism of action is:

  1. Monoclonal antibody that specifically binds TNF-alpha, blocking its interaction with TNF receptors → reduces inflammation
  2. Inhibits T-cell activation by blocking CD80/CD86
  3. Blocks interleukin-6 (IL-6) receptor
  4. Depletes B cells by targeting CD20
Show answer and explanation

Correct answer: A. Monoclonal antibody that specifically binds TNF-alpha, blocking its interaction with TNF receptors → reduces inflammation

  • A. Correct. Adalimumab (Humira) is a fully human monoclonal antibody (IgG1) that SPECIFICALLY BINDS TNF-ALPHA (tumor necrosis factor-alpha), a key pro-inflammatory cytokine. By blocking TNF-alpha from binding its receptors, it reduces inflammation. Used for: RA, psoriatic arthritis, Crohn's disease, ankylosing spondylitis, plaque psoriasis. Dental concern: increased infection risk (TNF is critical for granuloma maintenance against TB — screen for TB before starting).
  • B. CD80/CD86 blockade describes abatacept (Orencia) — inhibits T-cell co-stimulation.
  • C. IL-6 receptor blockade is the mechanism of tocilizumab (Actemra) — not adalimumab.
  • D. B-cell depletion via CD20 is rituximab (Rituxan) — different mechanism.

Practice Pharmacology questions Pharmacology study notes

More Pharmacology practice questions